#news #biotech Sangamo sinks as genome editing flunks early clinical test

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sangamo sinks as genome editing flunks early clinical test .Sangamo Therapeutics has posted lackluster data from a phase 1/2 trial of genome-editing therapy SB-913. The treatment failed to have the hoped-for effects on patients with the rare disease MPS II, causing investors to drive Sangamo’s stock down 30%. 

from FierceBiotech: Biotech http://bit.ly/2WMCdGq